DUBLIN–(BUSINESS WIRE)–The “Introduction to Veterinary Pharmacovigilance Training Course (Mar 9th – Mar 10th, 2026)” training has been added to ResearchAndMarketsDUBLIN–(BUSINESS WIRE)–The “Introduction to Veterinary Pharmacovigilance Training Course (Mar 9th – Mar 10th, 2026)” training has been added to ResearchAndMarkets

European Union Veterinary Pharmacovigilance Introductory Training Course: Practical Guidance and Basic Training for All Those Working in Drug Safety (Mar 9th – Mar 10th, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Introduction to Veterinary Pharmacovigilance Training Course (Mar 9th – Mar 10th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

This two-day event has been designed to provide an essential overview of veterinary pharmacovigilance and will offer practical guidance and basic training for all those working in drug safety in the EU.

Our experienced trainer will clarify roles and responsibilities, explain commonly used terminology and take participants through all the key aspects of this complex subject. There will be plenty of time for interaction and questions and answers to enable participants to get a good understanding of the issues involved. The use of industry case studies will demonstrate real-life scenarios to help embed learning.

Who Should Attend:

The course will be beneficial to those new to veterinary pharmacovigilance, support staff and experienced personnel who require a better understanding of drug safety in their current role. Adverse event monitoring and drug safety officers, together with regulatory affairs and personnel from registration departments, will also find this seminar useful.

Benefits of attending

  • Gain an overview of the European regulatory framework
  • Understand the requirements of the EU pharmacovigilance legislation
  • Learn about VICH
  • Understand adverse event reporting
  • Hear about causality assessment
  • Minimise the impact of data with errors
  • Get to grips with literature searches
  • Understand UK PV requirements post-Brexit

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Key Topics Covered:

Day 1

What is pharmacovigilance?

  • Beneficial and harmful effects of veterinary medicinal products
  • Key definitions

The current regulatory framework and its global impact

  • Overview of European regulatory framework, the EU pharmacovigilance legislation
  • Implications for global environment – link to VICH
  • Practical applications of definitions
  • Role of the MAH
  • Role of the NCA/EMA
  • Role of the QPPV

Adverse event reporting

  • Definitions
  • Impact of VICH guidelines
  • Expedited vs periodic
  • How to handle animal SARs
  • Handling human SARs
  • Understanding the wider scope of pharmacovigilance

Causality assessment

  • The principles of causality assessment with practical examples
  • Medical evaluation of individual reports of adverse events
  • Strategies for follow-up

Identifiable Reporter

Day 2

Do vets report AEs and why?

Electronic communication in pharmacovigilance

  • Reporting in EV Vet
  • VEDDRA

EV Vet demo

Minimising the impact of data with errors

  • Consistent assessment and coding

Clinical trial AE reporting requirements

  • Post-authorisation safety studies
  • Phase IV studies

Literature searches

  • Peer-reviewed worldwide literature
  • Local journals and magazines

PSURs

  • VMD (UK), VDD (Canada) and APVMA (Australia) requirements
  • Format and content of the PSUR
  • Analysis of data
  • Incidence calculation
  • Compliance and the PSUR

Speakers:

Declan O’Rourke

Director

Ortec PV Consultancy Ireland

Declan O’Rourke has over 20 years’ experience in industry where he has held technical, marketing, product development, clinical development, production and pharmacovigilance roles.

He is a veterinary surgeon, holds a Diploma in Marketing, a Master of Business Administration and a Fellowship of the Royal College of Veterinary Surgeons. He now directs Ortec PV Consultancy Ireland specialising in pharmacovigilance and represented IFAH-EU in the VICH Working Group on pharmacovigilance.

He is Honorary Associate Professor in Veterinary Pharmaceutical Development at Nottingham Veterinary School and Past President of British Cattle Veterinary Association.

For more information about this training visit https://www.researchandmarkets.com/r/9nnsg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

American Bitcoin’s $5B Nasdaq Debut Puts Trump-Backed Miner in Crypto Spotlight

American Bitcoin’s $5B Nasdaq Debut Puts Trump-Backed Miner in Crypto Spotlight

The post American Bitcoin’s $5B Nasdaq Debut Puts Trump-Backed Miner in Crypto Spotlight appeared on BitcoinEthereumNews.com. Key Takeaways: American Bitcoin (ABTC) surged nearly 85% on its Nasdaq debut, briefly reaching a $5B valuation. The Trump family, alongside Hut 8 Mining, controls 98% of the newly merged crypto-mining entity. Eric Trump called Bitcoin “modern-day gold,” predicting it could reach $1 million per coin. American Bitcoin, a fast-rising crypto mining firm with strong political and institutional backing, has officially entered Wall Street. After merging with Gryphon Digital Mining, the company made its Nasdaq debut under the ticker ABTC, instantly drawing global attention to both its stock performance and its bold vision for Bitcoin’s future. Read More: Trump-Backed Crypto Firm Eyes Asia for Bold Bitcoin Expansion Nasdaq Debut: An Explosive First Day ABTC’s first day of trading proved as dramatic as expected. Shares surged almost 85% at the open, touching a peak of $14 before settling at lower levels by the close. That initial spike valued the company around $5 billion, positioning it as one of 2025’s most-watched listings. At the last session, ABTC has been trading at $7.28 per share, which is a small positive 2.97% per day. Although the price has decelerated since opening highs, analysts note that the company has been off to a strong start and early investor activity is a hard-to-find feat in a newly-launched crypto mining business. According to market watchers, the listing comes at a time of new momentum in the digital asset markets. With Bitcoin trading above $110,000 this quarter, American Bitcoin’s entry comes at a time when both institutional investors and retail traders are showing heightened interest in exposure to Bitcoin-linked equities. Ownership Structure: Trump Family and Hut 8 at the Helm Its management and ownership set up has increased the visibility of the company. The Trump family and the Canadian mining giant Hut 8 Mining jointly own 98 percent…
Share
BitcoinEthereumNews2025/09/18 01:33
Current Week Is the Third Worst Week Historically for BTC

Current Week Is the Third Worst Week Historically for BTC

The post Current Week Is the Third Worst Week Historically for BTC appeared on BitcoinEthereumNews.com. The 38th week of the year is historically the third-worst performing week for bitcoin, averaging a return of -2.25%. Only week 28 (-2.78%) and week 14 (-3.91%) have been weaker historically, according to Coinglass data. This week, bitcoin is already down nearly 2%, trading around $113,000, with September’s monthly options expiry pointing to a max pain level at $110,000, according to Deribit, this could imply further downside. Max pain refers to the strike price at which the largest number of options contracts (calls and puts) expire worthless, effectively maximizing losses for option buyers. In addition, market enthusiasm has faded. Perpetual funding rates for bitcoin, which measure the ongoing cost of holding leveraged long or short positions in perpetual futures contracts, have dropped to 4%, one of their lowest levels in a month. A low positive funding rate suggests reduced demand for leveraged long exposure, often signaling that speculative froth in the market has cooled. While, implied volatility (IV), which reflects market expectations for future price swings, is also near historic lows at 37. Despite the weekly dip, bitcoin remains 4% higher in September and up 6% for the quarter. With roughly 14 weeks left in the year and most of those weeks historically producing positive returns, this may represent calm before potential volatility. Meanwhile, gold has continued its impressive rally, climbing another 1% on Tuesday and now more than 42% higher year to date, which continues to take the sting out of bitcoin. Another factor weighing on bitcoin sentiment is the massive gains in artificial intelligence and high-performance computing stocks, for example IREN (IREN), which may have taken some shine away from bitcoin in the short term. Source: https://www.coindesk.com/markets/2025/09/23/bitcoin-stumbles-in-week-38-its-third-worst-week-on-average
Share
BitcoinEthereumNews2025/09/23 21:04
“Major US bank blows up from Silver trade” headlines hide the $675M margin shock currently hitting traders

“Major US bank blows up from Silver trade” headlines hide the $675M margin shock currently hitting traders

This week started with a sensational screenshot shared across hundreds of breathless posts on X, and a claim designed to hit every financial nerve ending at once
Share
CryptoSlate2025/12/30 05:25